Training activity information
Details
Perform analysis of the segregation of chromosomes following chromosomal rearrangements; determine implications for recurrence risk and future testing.
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
What are the intended outcomes of the training activity?
- How will you prepare to perform chromosomal analysis for patients with rare diseases to identify these specific rearrangements?
- What do you need to know before embarking on the activity? Consider reviewing the clinical mechanisms of infertility and recurrent miscarriage, the specific types of rearrangements involved (such as translocations or inversions), and how to perform recurrence risk calculations.
- How will you prepare to evaluate the implications for future testing for both the patient and their family members?
What do you anticipate you will learn from the experience?
- What specific insights do you hope to gain from this activity, particularly regarding how the size and gene content of a rearranged segment influence the clinical significance and phenotypic risk of an unbalanced offspring?
- Thinking about what you already know about cytogenetics and variant interpretation, how do you expect this activity to improve your ability to move from simply identifying a rearrangement to predicting its inheritance patterns?
What actions will you take in preparation for the experience?
- How do you plan to gain clarity on the use of Bayesian calculations or risk assessment tools in these cases?
- What possible challenges do you anticipate—such as predicting risks for complex or rare rearrangements with limited literature—and how have you planned to handle them?
- Identify how you feel about embarking on this training activity; given that your analysis and risk assessment will directly inform future reproductive options for a family, how are you preparing for this level of professional responsibility?
In action
What are you doing?
- How are you approaching the analysis of chromosomal segregation (e.g., alternate, adjacent-1, or adjacent-2) for the specific rearrangement identified?
- What real-time decisions are you making as you determine which gametes are balanced, unbalanced, or normal?
- Which parts of the task—such as identifying the type of rearrangement—feel intuitive, and which—such as calculating recurrence risks or determining the implications for future testing—require more conscious effort?
How are you progressing with the activity?
- How effective are your current actions in accurately predicting the possible genomic outcomes for offspring?
- What technical or clinical challenges are you facing in the moment—such as a complex translocation with multiple break points—and what are you learning as the analysis progresses?
- How does this activity connect to your existing knowledge of rare disease investigations and chromosomal analysis?
- Are you successfully identifying the clinical significance of the potential unbalanced segments you are modelling?
How are you adapting to the situation?
- Are there alternative segregation patterns or risks (such as 3:1 segregation) you should be considering for this specific case?
- What immediate support or guidance do you need to verify your risk calculations or future testing recommendations?
- As you determine these implications, are you ensuring that you are working strictly within your professional scope of practice?
- How are you adapting your approach if the clinical history (e.g., a history of multiple miscarriages versus a child with a specific phenotype) changes your interpretation of the risk?
On action
What did you notice?
- Summarise the key points of the activity, specifically the steps you took to model the segregation patterns (e.g., alternate, adjacent-1, adjacent-2) of the identified chromosomal rearrangement.
- What were the essential clinical or technical details—such as a specific parental balanced translocation or a history of recurrent miscarriage—that most significantly influenced your recurrence risk calculations?
What did you learn from the activity?
- What specific skills or knowledge did you develop regarding performing chromosomal analysis and determining the implications of rearrangements for rare disease investigations?
- How has this experience improved your ability to apply Bayesian calculations or other risk assessment tools to determine the likelihood of future unbalanced offspring?
- Were there any unexpected challenges or successes during the analysis—such as identifying a high risk for 3:1 segregation—and what did you learn from these?
- In what ways did your reflection-in-action (the real-time decisions you made while modelling gamete outcomes) influence the final conclusions of your analysis?
- How does the ability to accurately predict inheritance patterns and recurrence risks relate to the requirements for your post-programme practice as a Clinical Scientist?
What will you take from the experience moving forward?
- What specific areas for continued development in cytogenetics or genetic risk assessment have you identified as a result of this activity?
- How can you apply the learning from this experience to your routine practice to ensure you consistently provide accurate information regarding future reproductive options for families?
- Identify the specific actions you will now take—such as reviewing literature on specific rare rearrangements or practicing further risk calculation scenarios—to support the assimilation of what you have learned.
- What support or resources (e.g., senior clinical scientist mentorship, specialist risk-assessment software, or best practice guidelines) do you need to further develop your expertise in this area?
Beyond action
Have you revisited the experiences?
- How has your perspective on performing chromosomal analysis and evaluating segregation patterns evolved as you have encountered a wider range of rearrangements in your daily practice?
- Comparing these experiences with your Observed Training Activities (OTAs)— what specific observable behaviours and technical proficiencies have you assimilated into your routine practice?
- As part of a module review, what recurring themes have you identified regarding the clinical impact of meiotic segregation on family recurrence risks by revisiting reflections from multiple training activities?
- Through discussions with senior colleagues or peers, has your understanding of how to manage complex families or rare rearrangements changed as a result of that mutual exchange?
How have these experiences impacted upon your current practice?
- Recognising that these tasks are not isolated incidents, how has this experience supported your development in wider areas, such as writing interpretative reports or providing patient management recommendations for the wider family?
- How have you applied the knowledge of segregation patterns and risk calculation gained from this activity since the original experience to improve the safety and quality of the genomic service you provide today?
- How is the learning from these investigations supporting your preparation for ‘in-person’ assessments for this module, such as Case-based Discussions (CBDs) or Direct Observations of Practical Skills (DOPS) related to variant classification and risk assessment?
How might these experiences contribute towards your future practice?
- What transferable skills—such as the ability to synthesise complex mathematical risk models with diverse clinical histories—are you continuing to develop as you move toward becoming a Clinical Scientist?
- What clear actions have you identified for the continued development of your specialist knowledge in meiotic segregation to ensure you consistently deliver high-quality, patient-centred care in your future post-programme practice?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 2 |
Outcome
Perform targeted and chromosomal analysis for patients referred for investigation of rare disease. |